Shay Capital’s Cardiff Oncology CRDF Stock Holding History

Shay Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,862	Closed	-$90.5K	–	338
2024 Q4	$90.5K	Buy	+20,862	New	+$65.2K	0.01%	280

Other funds holding CRDF

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Shay Capital's CRDF Position: Q1 2025 in Review

Shay Capital sold out of Cardiff Oncology (CRDF) in Q1 2025, closing a stake of 20,862 shares — an estimated $90.5K sold.

Shay Capital first reported a position in CRDF in Q4 2024 and held it in 1 quarter. The position peaked at $90.5K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2025.

Shay Capital reported no remaining Cardiff Oncology position as of Q1 2025 after selling out during the quarter.
Shay Capital sold 20,862 Cardiff Oncology shares in Q1 2025, an estimated $90.5K.
Shay Capital first reported a position in Cardiff Oncology in Q4 2024 and held it in 1 quarter.
Shay Capital's Cardiff Oncology position peaked at $90.5K in Q4 2024.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.